Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,952.00
Bid: 1,951.00
Ask: 1,953.00
Change: -24.00 (-1.21%)
Spread: 2.00 (0.103%)
Open: 1,968.00
High: 1,976.00
Low: 1,946.00
Prev. Close: 1,976.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Hikma Pharma's founding family capitalise on share price slump

Thu, 01st Sep 2016 15:25

(ShareCast News) - Three Hikma Pharmaceuticals directors, including chairman and chief executive Said Darwazah, took the opportunity to each snap up £3m worth of shares in the drugmaker as the stock slumped to its lowest level since early April.Darwazah and his brothers, vice chairman Mazen, sons of founder Samih, on Wednesday bought 140,000 shares apiece at a price of 2,150p on the last day before the shares went ex-dividend, adding them to the holdings of the family's Darhold investment vehicle.Non-executive Ali Al-Hursy, who also has an equity stake in Darhold, also snapped up 140,000 shares via the vehicle.CEO Said now holds a combined direct and indirect stake of 5.59%, while Mazen has 3.06% and Al-Hursy 2.44%.Said's purchase followed his £4.3m acquisition last week at a price of 2,160p after comments by US presidential hopeful Hillary Clinton about the escalating cost of drugs sent the sector lower.As the stock went ex-dividend on Thursday, Hikma's shares were down almost 3% to just above a five-month low.On 24 August Hikma said it still expected to produce full-year revenue of at least $2bn but reported a drop in operating profit despite a jump in first-half revenues.Claiming a transitional year as it integrates its West-Ward Columbus acquisition, operating profits slipped to $176m from $204m due to a lower contribution from the generics business.However, the FTSE 250 company still declared an interim dividend of 11 cents per share, in line with the dividend in the same period last year. Top Director BuysHikma Pharmaceuticals (HIK)Director name: Darwazah,MazenAmount purchased: 140,000 @ 2,150.00pValue: £3,010,000.00Hikma Pharmaceuticals (HIK)Director name: Darwazah,SaidAmount purchased: 140,000 @ 2,150.00pValue: £3,010,000.00Hikma Pharmaceuticals (HIK)Director name: Al-Husry,AliAmount purchased: 140,000 @ 2,150.00pValue: £3,010,000.00Octagonal (OCT)Director name: David Davison,Martin Amount purchased: 1,000,000 @ 195.00pValue: £1,950,000.05Aviva (AV.)Director name: Mire,MichaelAmount purchased: 35,000 @ 432.50pValue: £151,374.99Hss Hire Group (HSS)Director name: Quested,PaulAmount purchased: 47,000 @ 85.00pValue: £39,950.00Pz Cussons (PZC)Director name: Silver,CarolineAmount purchased: 10,000 @ 333.15pValue: £33,315.00Elementis (ELM)Director name: Waterman ,Paul Amount purchased: 8,168 @ $2.99Value: $19,059.11Octagonal (OCT)Director name: David Davison,Martin Amount purchased: 1,000,000 @ 1.90pValue: £19,000.00Third Point Offshore Investors Ltd. Gbp Shares (TPOG)Director name: Legg,Christopher F LAmount purchased: 1,500 @ $14.45Value: $16,915.11European Assets Trust (EAT)Director name: Bond,Julia Amount purchased: 652 @ 1,072.60pValue: £6,993.35Blackrock World Mining Trust (BRWM)Director name: Lewis,JaneAmount purchased: 2,429 @ 286.19pValue: £6,951.49Elementis (ELM)Director name: Waterman ,Paul Amount purchased: 1,832 @ $2.98Value: $4,260.47Legal & General Group (LGEN)Director name: Markham,RudyAmount purchased: 1,463 @ 211.54pValue: £3,094.83Legal & General Group (LGEN)Director name: Meddings,Richard HAmount purchased: 1,186 @ 211.54pValue: £2,508.86Legal & General Group (LGEN)Director name: Popham,StuartAmount purchased: 772 @ 211.54pValue: £1,633.09Legal & General Group (LGEN)Director name: Bradley ,Carolyn Amount purchased: 731 @ 211.54pValue: £1,546.36Record (REC)Director name: Cullen,SteveAmount purchased: 1,919 @ 25.65pValue: £492.22Henderson Group (HGG)Director name: Thompson ,Roger Amount purchased: 63 @ 240.03pValue: £151.22Henderson Group (HGG)Director name: Formica,AndrewAmount purchased: 62 @ 240.03pValue: £148.82Henderson Group (HGG)Director name: Wagstaff ,Philip Amount purchased: 52 @ 240.03pValue: £124.81
More News
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:42

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.